Managing metabolic complications of peritoneal dialysis

Clinical Nephrology

Volumn 62, Issue 1, 2004, Pages 35-43

  Pennell, P ^a   Rojas, C ^b   Asif, A ^a   Rossini, E ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Gambro Healthcare   (United States)

Author keywords

Dyslipidemia; Hyperglycemia; Metabolic complications; Obesity; Peritoneal dialysis

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DIET THERAPY; DIETARY FIBER; DYSLIPIDEMIA; EXERCISE; EXPERIENCE; FEMALE; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; PERITONEAL DIALYSIS; PROTEIN DIET; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 3242746850     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp62035     Document Type: Article

References (21)

1. Attman P, Samuelsson O, Alaupovic P 1993 Lipoprotein metabolism and renal failure. Am J Kidney Dis 21: 573-592
2. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N 1992 The uremic dyslipidemia: a cross-sectional and longitudinal study. Am J Kidney Dis 20: 324-335
3. Bagdade JD, Alpers JJ 1977 Plasma high-density lipoprotein concentrations in chronic hemodialysis and renal transplant patients. N Engl J Med 296: 1436-1439
4. Bofinger A, Westhuyzen J, Saltissi D, Morgan C, Healy H 1997 Low-density lipoprotein subtraction profiles in dialysis patients. Nephrology 3: 169-177
5. Cheng SC, Chu TS, Huang KY, Chen YM, Chang WK, Tsai TJ, Wu KD 2001 Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int 21: 282-289
6. Cocchi R, Viglino G, Cancarini G, Catizone L, Favazza A, Tommasi A, Salomone M, Segoloni GP, Torpia R, Giangrande A 1996 Prevalence of hyperlipidemia in a cohort of CAPD patients. Italian Cooperative Peritoneal Dialysis Study Group (ICPDSG). Miner Electrolyte Metab 22: 22-25
7. Fried L, Hutchison A, Stegmayr B, Prichard S, Bargman JM 1999 Recommendations for the treatment of lipid disorders in patients on peritoneal dialysis. Perit Dial Int 19: 7-16
8. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, Krauss RM 1997 Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 95: 2022-2026
9. Kagan A, Bar-Khayim Y, Schafer z, Fainaru M 1990 Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 37: 980-990
10. Levey AS, Beto JA, Coronado-BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PWF, Wright JT 1998 Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 32: 853-906
11. Lindholm B, Norbeck HE 1986 Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 220: 143-151
12. Little J, Phillips L, Russell L, Griffiths A, Russell L, Davies SJ 1998 Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity and dialysis factors. J Am Soc Nephrol 9: 1931-1939
13. Massy ZA, Ma JZ, Louis TA, Kasiske BL 1995 Lipid-lowering therapy in patients with renal disease. Kidney Int 48: 188-198
14. Morrison G 1989 Metabolic effects of continuous ambulatory peritoneal dialysis. Ann Rev Med 40: 163-172
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) 1993 Summary of the second report. JAMA 269: 3015-3023
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2000 Executive summary of the third report. JAMA 285: 2486-2497
17. National Institutes of Health (NIH) 2002 Guidelines on Overweight and Obesity:ElectronicTextbook. http://www.nhlgi.nih.gov/guidelines/obesity/e_txbk/index.htm
18. National Kidney Foundation (NKF) 2003 K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Disease 41: S1-S91
19. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H 1999 Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int 56 (Suppl 71): S134-S136
20. Shoji T, Nishizawa Y, Kawagishi T, Kaasaki K, Taniwaki H, Tabata T, Inoue T, Morii H 1998 Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9: 1277-1284
21. Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y 2001 Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 38 (Suppl 1): S30-S33